Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

BACKGROUND: Hereditary angioedema (HAE) due to C1 inhibitor deficiency manifests as recurrent swelling attacks that can be disabling and sometimes fatal. Long‐term prophylaxis with twice‐weekly intravenous injections of plasma‐derived C1‐inhibitor (pdC1‐INH) has been established as an effective trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuraw, B. L., Cicardi, M., Longhurst, H. J., Bernstein, J. A., Li, H. H., Magerl, M., Martinez‐Saguer, I., Rehman, S. M. M., Staubach, P., Feuersenger, H., Parasrampuria, R., Sidhu, J., Edelman, J., Craig, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755045/
https://www.ncbi.nlm.nih.gov/pubmed/26016741
http://dx.doi.org/10.1111/all.12658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755045/
https://www.ncbi.nlm.nih.gov/pubmed/26016741
http://dx.doi.org/10.1111/all.12658

Ejemplares similares